

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d)**  
**of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported)**  
**August 17, 2021**

---

**ORIC Pharmaceuticals, Inc.**  
(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-39269**  
(Commission  
File Number)

**47-1787157**  
(IRS Employer  
Identification No.)

**240 E. Grand Ave, 2nd Floor**  
**South San Francisco, CA 94080**  
(Address of principal executive offices, including zip code)

**(650) 388-5600**  
(Registrant's telephone number, including area code)

**Not Applicable**  
(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value \$0.0001 per share	ORIC	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

---

---

---

**Item 8.01 Other Events.**

As previously disclosed, Dominic Piscitelli, the Chief Financial Officer of ORIC Pharmaceuticals, Inc. (“ORIC”) received a subpoena for documents and information, in his personal capacity, from the Securities and Exchange Commission (the “SEC”) in March 2020 related to an SEC investigation into the trading of securities of certain other companies unrelated to ORIC. On August 17, 2021, Mr. Piscitelli received a letter from the SEC indicating that the SEC has concluded its investigation as to Mr. Piscitelli without recommending further action at this time.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

### **ORIC PHARMACEUTICALS, INC.**

Date: August 18, 2021

By: /s/ Jacob M. Chacko, M.D.

Jacob M. Chacko, M.D.

President and Chief Executive Officer